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AbstrAct
background. Before the advent of neoadjuvant chemotherapy, radiotherapy and surgery alone were associated with a 
high risk of uncontrolled locoregional relapses in locally advanced breast cancer (LABC).
Material and methods. In the 1990s we initiated two neoadjuvant protocols, where patients with LABC were given 
either doxorubicin qW or 5-fluorouracil/mitomycin (FUMI) q3W to shrink the tumours prior to mastectomy and 
postoperative radiotherapy. Previously, we reported TP53 mutation status to predict a poor response to chemotherapy. 
Here, we present the long-term survival data, with a follow-up of 20 years in the doxorubicin (n  90) and 15 years in 
the FUMI trial (n  34).
results. Patients in the doxorubicin trial with TP53-mutated tumours experienced a shorter recurrence-free (RFS; 14 
vs. 83 months, p  0.001) and overall survival (OS; 35 vs. 90 months, p  0.001) than patients with TP53 wt tumours. 
Similarily, TP53 mutations were associated with a shorter OS (22 vs. 80 months, p  0.03) and a tendency to shorter 
RFS (17 vs. 33 months, p  0.06) in patients treated with FUMI. Furthermore, axillary lymph node metastases predicted 
shorter OS, but only in patients treated with doxorubicin (49 vs. 142 months, p  0.04). Applying multivariate analysis, 
TP53 mutations predicted inferior RFS (p  0.001) as well as OS (p  0.001), independently of axillary lymph node 
status. Isolated local recurrences, without simultaneous distant metastases, occurred in seven patients only in the two 
trials. Interestingly, chest wall radiation fibrosis predicted improved OS (p  0.004).
conclusion. TP53 inactivating mutations are associated with an inferior long-term prognosis in patients with LABC 
treated with conventional chemotherapy.
Traditionally treated with radiotherapy, with or with-
out additional surgery, patients with locally advanced 
breast cancer (LABC) frequently experienced intrac-
table locoregional relapses and subsequently died of 
their disease [1–5]. Following the implementation of 
chemotherapy regimens for metastatic breast cancer, 
and subsequent, adjuvant therapy in early breast can-
cer, studies were undertaken to test these regimens 
as primary treatment of LABC [3,4,6,7].
in 1991, we initiated our first clinical trial in 
LABC evaluating low-dose, weekly doxorubicin [8,9], 
a regimen commonly used for metastatic breast can-
cer at that time [10,11]. subsequently, from 1997, we 
conducted a trial in which we applied a combined 
regimen of 5-fluorouracil and mitomycin (FUMi) 
to patients with LABC [12], based on promising 
concurrent data from patients with metastatic breast 
cancer [13,14]. Both protocols included pre- 
treatment snap-frozen surgical biopsies for predictive 
factor analysis. Previously, we reported TP53 muta-
tion status to predict for an inferior anti-tumour 
response in both studies [9,12]. While others have 
reported the prognostic impact of TP53 mutation sta-
tus [15–17], the long-term (10 years and beyond), 
relapse-free and overall survival (Os) data with 
respect to TP53 mutation status in patients treated 
with defined drug regimens in prospective studies are 
lacking. Here, we report the long-term outcome for 
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all patients participating in the doxorubicin and 
FUMi trials, with a cut-off time from patient inclu-
sion to final update of the database of 20 years for 
the doxorubicin and 15 years for the FUMi study.
Material and methods
Patient and tumour characteristics are given in Table i. 
Apart from human epidermal growth factor receptor 
2 (HEr2) analysis these characteristics are based 
upon data published previously [9,12]. HEr2 fluo-
rescent in situ hybridisation (FisH) was performed 
on fresh frozen tumour samples using the Vysis Lsi 
TOP2A spectrumOrange/HEr-2 spectrumgreen/
CEP 17 spectrumAquaTM Probe kit. Unfortunately, 
breast cancer tissue for HEr2 FisH analysis was 
available only from 30 patients (of 90) in the doxo-
rubicin trial. TP53 mutation status was assessed by 
cDNA sequencing previously, and predicted for infe-
rior drug response and worse short-term survival in 
both studies [8,9]. in the current analysis, we evalu-
ated the long-term prognostic impact of TP53 muta-
tion status with respect to rFs as well as Os.
Both trials enrolled patients suffering from LABC 
(T3/T4 and/or N2/N3), considered unfit for primary 
surgery. Common to both trials, all patients underwent 
staging with x-ray imaging of the chest, spine, and pel-
vis, liver ultrasound examination and a bone scan before 
commencing chemotherapy. As the primary aim of 
both protocols were to: 1) downstage locally advanced 
tumours, making them fit for surgery, and 2) evaluate 
factors predicting response to therapy, patients with 
LABC and limited distant metastases for whom opti-
mal local therapy was defined as the primary therapeu-
tic target were eligible for inclusion. The study protocols 
were approved by the regional Ethical Committee of 
the Western health region in Norway (reference num-
bers: 192/91-69.91, 39/92-69.91 and 06/597), and all 
patients gave their informed consent before inclusion.
Study I
Doxorubicin (14 mg/m2) was administered i.v. 
weekly, scheduled for 16 weeks, with four-weekly 
assessment of clinical response. Ninety patients were 
included in the final analysis [9]. Of these, 78 patients 
did not reveal any signs of distant metastases at the 
time of diagnosis. All patients were enrolled between 
January 1991 and March 1997.
Study II
in the FUMi trial 5-fluorouracil 1000 mg/m2 day 1 
and 2 and mitomycin 6 mg/m2 day 2 was adminis-
tered i.v. every three weeks, scheduled for a total of 
four cycles, with assessment of clinical response 
before every cycle. Thirty-four patients were included 
in the final analysis [12]. Of these, 24 patients did 
not reveal any signs of distant metastases at the time 
of diagnosis. All patients were enrolled between June 
1993 and February 2001.
response rates and short-term survival data in the 
doxorubicin and FUMi trials have been described in 
detail previously [9,12]. Clinical response was evalu-
ated according to the UiCC criteria, commonly used 
at that time. The primary scientific aim of the trials was 
to identify potential biomarkers predictive of drug 
resistance, defined as tumours with progressive disease 
(PD). The prescribed treatment was stopped if PD 
occurred. Doxorubicin was the only chemotherapy 
used presurgically in study i, apart from one patient 
included in 1997 who received docetaxel as second line 
treatment subsequent to progressing on doxorubicin. 
in study ii, seven patients switched to docetaxel and 
Table i. Baseline patient and tumour characteristics.
study i
Doxorubicin
study ii
FUMI
Accrual period Jan 1991–Mar 1997 Jun 1993–Feb 2001
Age (years)
range 32–88 37–82
median 64 67
T stage
T21 3 2
T3 54 15
T4 33 17
N stage
N02 30 9
N1 34 14
N2 26 11
M stage
M0 78 24
M1 12 10
Tumour type
iDC 75 30
iLC 8 43
Other 7
grade
i 23 0
ii 42 16
iii 25 18
Er status
Negative4 13 11
Positive 77 23
HEr2 status
Negative5 24 27
Positive 6 6
No data 60 1
TP53 status
TP53 wt 64 16
TP53 mut. 26 18
TP53 wt  non 
L2/L3 mut.
71 24
TP53 L2/L3 mut 19 10
 iDC, infiltrating ductal carcinoma; iLC, infiltrating lobular 
carcinoma.
1T stage and all subsequent tumour characteristics given for stage 
3 and 4 combined. T2 tumours only included if axilla stage N2; 
2N stage by clinical assessment alone; 3iLC or poorly differentiated, 
not subclassified further; 4Er negative if tumour Er concentration 
 10 fmol/mg; 5HEr2 in situ hybridisation.
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 Locally advanced breast cancer and TP53  1349
eight patients to anthracyclines due to inadequate 
tumour response on FUMi. The reason for not switch-
ing more patients to another cytotoxic regimen in 
study i was the lack of alternative, potent drugs until 
the introduction of taxanes in the late 1990s.
Following chemotherapy, patients went on to 
mastectomy with surgical exploration of the axilla 
(removal of enlarged lymph nodes) and radiotherapy 
to the chest wall, axilla and supraclavicular fossa. 
Patients deemed inoperable subsequent to primary 
chemotherapy (n  11 in the doxorubicin and n  11 
in the FUMi trial) received radiotherapy alone to the 
breast and regional lymph nodes. radiotherapy was 
administered as 50 gy/25 fractions to the chest wall 
(or breast) and axilla and 48 gy/24 fractions to the 
supraclavicular area. Additionally, two patients with 
stable disease (sD) and one patient with partial 
response (Pr) in the two trials combined received a 
radiotherapy boost (10 gy/5 fractions) due to tumour-
on-ink in the pathological mastectomy specimen.
Patients with an oestrogen or progesterone recep-
tor positive breast cancer (Er or Pgr  10 fmol/mg 
protein) received adjuvant tamoxifen 30 mg daily for 
five years in both studies. Er/Pgr levels were mea-
sured as described previously [18], and Er positivity 
set at  10 fmol/mg is in accordance with tumours 
considered Er positive by immunohistochemistry in 
routine diagnostics today [19]. The median follow-up 
time was defined from inclusion in the study up to 
25 April 2013 (234 months for the doxorubicin 
study, 177 months for the FUMi study). recur-
rence-free survival (rFs) was calculated for patients 
with stage 3 disease, and defined as the time from 
inclusion to a clinical or radiological confirmed 
recurrence of breast cancer, whereas Os was assessed 
for stage 3 and stage 3/4 separately. in a patient with 
PD who never became disease-free, the rFs was set 
as zero.
Conflicting evidence has linked radiation-induced 
fibrosis to subsequent local tumour control [20–22]. 
Based on clinical observations, we hypothesised that 
patients in the two trials who developed extensive 
radiation fibrosis would have an improved survival 
outcome. A total of 46 patient records contained data 
regarding chest wall status during long-term fol-
low-up. For these patients, the correlation between 
radiation fibrosis and tumour response to chemo-
therapy as well as Os was assessed. Furthermore, 
data regarding the expression of the DNA repair 
enzyme ataxia telangiectasia mutated (ATM) was 
extracted from a recently conducted study [23] and 
analysed for its relationship to radiation fibrosis.
Statistical analysis
survival analysis was performed by kaplan-Meier 
plots, and patient subgroups were compared by the 
log-rank test. Deaths for reasons other than breast 
cancer, or patients still alive at the time of analysis, 
were treated as censored observations. Multivariate 
survival analysis was performed using Cox regres-
sion. Mann-Whitney rank test was used for com-
parison of ATM levels between patients’ subgroups, 
whereas Fisher Exact test was used to compare the 
number of patients with radiation fibrosis in the dif-
ferent response groups. All statistical analyses were 
performed using the sPss 15.0/PAsW 17.0 soft-
ware package (sPss inc.) and/or simple interactive 
statistical Analysis (sisA). All p-values reported are 
two-tailed.
Results
in the doxorubicin trial, median rFs (stage 3 disease 
only) and Os (stage 3 & 4) was 48 months and 56 
months, respectively, in the total cohort, with an Os 
of 67 months if patients with distant metastases at 
inclusion (n  12) were excluded from the analysis 
(Figure 1A, B). in the FUMi trial, the median rFs 
and Os was 22 and 32 months, respectively, with an 
Os of 35 months if patients with distant metastases 
(n  10) were excluded (Figure 1C, D).
response rates were reported previously [9,12]. 
Thus, while 38% and 32% (stage 3 & 4 combined) 
of the patients obtained Pr in the doxorubicin and 
FUMi studies respectively, no patient obtained a 
complete response in neither study [9,12]. The long-
term survival data for the different response groups 
are given in Figure 1E, H. Patients obtaining a PD 
on doxorubicin had significantly worse survival 
outcome than those who responded with sD or Pr 
(Figure 1E, F), whereas no significant difference in 
survival between the response groups was recorded 
in the FUMi trial (Figure 1g, H). When we com-
pared the survival outcome between patients obtain-
ing a Pr versus patients having a sD, no significant 
difference was recorded either within the doxorubi-
cin or within the FUMi group (Figure 1E–H). 
in patients who derived a clinical benefit (Pr or sD) 
from the neoadjuvant chemotherapy, the frequency 
of local recurrences was 21% in the doxorubicin and 
28% in the FUMi trial. in general, these local 
relapses occurred synchronous to distant metasta-
ses; 18 of 22 cases in the doxorubicin and 10 of 13 
cases in the FUMi trial). isolated local recurrences, 
without simultaneous distant metastases, occurred 
only in four patients in the doxorubicin and three 
patients in the FUMi trial. A clinically negative 
axilla (N0 versus N1/2) prior to chemotherapy was 
associated with improved long-term outcome in the 
doxorubicin, but not the FUMi trial (Figure 2A–D). 
No effect of tumour T-stage (T2/3 vs. T4) on 
survival outcome was recorded in the two trials 
(Figure 2E–H). Also, no effect of hormone receptor 
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R
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R
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O
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Dox
Stage 3 (n=78)
FUMI
Stage 3 (n=24)
Dox
Stage 3 (n=78)
FUMI
Stage 3 (n=24)
Time (months) Time (months)
FUMI
−−PR (9)
−−SD (9)
−−PD (6)
Dox
−−PR (30)
−−SD (39)
−−PD (9)
p=0.79p=0.78
p=0.011p<0.0001
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Time (months)Time (months)
Dox
−−PR (30)
−−SD (39)
−−PD (9)
FUMI
−−PR (9)
−−SD (9)
−−PD (6)
Figure 1. (A–D) recurrence-free and overall survival in patients with locally advanced breast cancer after neoadjuvant doxorubicin (Dox) 
qW (16 weeks) or 5-FU/mitomycin (FUMi) q3w (12 weeks). (E–H) survival related to tumour response group. Os, overall survival; PD, 
progressive disease; Pr, partial response; rFs, recurrence-free survival; sD, stable disease. Number of patients per group given in 
parenthesis (patients with stage iV disease excluded). Censored values are marked with .
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Figure 2. survival related to pre-treatment clinical nodal (N) status (A–D) and tumour T-stage (E–H) in patients with locally advanced 
breast cancer given neoadjuvant doxorubicin or FUMi. Os, overall survival; rFs, recurrence-free survival. Number of patients per group 
given in parenthesis (patients with stage iV disease excluded). Censored values are marked with .
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status on long-term survival outcome was recorded 
in neither trial (data not shown). Breast cancer- 
specific mortality was 58% in the doxorubicin trial 
(52 of 90 patients) and 44% in the FUMi trial 
(15 of 34 patients), based on 20 and 15 years of 
follow-up.
Tumour TP53 mutations were detected in 34% 
of the patients included in the doxorubicin and 
FUMi trials (Table i), whereas mutations in the 
essential L2/L3 DNA binding domains of TP53 
occurred in 22% of the breast cancers [9,12]. Both 
TP53 mutations in total (Figures 3A, B) and TP53 
mutations affecting the L2/L3 domains (Figures 3C, 
D) were associated with significantly inferior rFs as 
well as Os in the doxorubicin trial. TP53 mutations 
were associated with a borderline significant decline 
in rFs, and a significant decline in Os after FUMi 
treatment (Figure 3E, F). No significant effect was 
detected for TP53 mutations affecting the L2/L3 
domains in the FUMi trial (Figure 3g, H), probably 
due to the low number of patients without distant 
metastases at diagnosis (n  24). Combining patients 
from the two trials, TP53 mutations were associated 
with a significantly reduced rFs (p  0.001) and Os 
(p  0.001), whereas TP53 mutations affecting the 
L2/L3 domains were associated with a shortened Os 
(p  0.006), but not a shorter rFs (p  0.06). TP53 
was mutated in four of seven patients who developed 
isolated local recurrences, without simultaneous dis-
tant metastases, in the two trials combined. Cox mul-
tivariate analysis was used to decipher whether TP53 
mutation status or nodal status independently pre-
dicted survival outcome, and TP53 mutation status 
remained the sole parameter predicting survival in 
the doxorubicin and FUMi trials, including the com-
bined analysis of the two trials (Figure 4).
An observational finding was the impact of chest 
wall fibrosis on long-term outcome. radiation fibro-
sis developed in 19 of 46 patients whose chest wall 
status was described in the patient records (Pr, sD 
and PD combined), and these patients derived a 
significantly prolonged Os (median: 139.5 months, 
p  0.004), compared to those who did not develop 
fibrosis (median: 25.5 months). Due to the limited 
number of patients for whom this parameter was 
recorded it could not be entered into a multivariate 
model. This survival benefit in patients with fibrosis 
was evident both in chemotherapy responders (Pr) 
and non-responders (sD and PD), and it was not 
related to differences in radiation dose in-between 
the patients. Furthermore, the improved survival in 
patients developing chest wall fibrosis was not 
related to TP53 mutation status, nor was it related 
to ATM expression levels previously found to be 
associated with response to chemotherapy in these 
patients [23].
Discussion
We demonstrated in 1996 that TP53 mutations 
predict a lack of response to low-dose doxorubicin 
[8]. This observation was later reconfirmed following 
an expansion of the initial trial [9], in addition to our 
subsequent study [12] evaluating the impact of TP53 
status on response to the FUMi regimen. in addi-
tion, studies by the breast cancer group in Vienna 
[24] as well as a recent study by our group [25] 
both reported a low response rate for TP53-mutated 
primary breast cancers treated with anthracyclines at 
three-weekly conventional doses. importantly, while 
TP53 mutations are associated with a lack of sensitiv-
ity to anthracyclines and related compounds, and 
inferior short-term survival [9,17], the impact of 
TP53 mutation status on long-term outcome, beyond 
10 years, has not been fully elucidated in a controlled 
setting. Here, we report the long-term prognostic 
effect of TP53 mutation status at 20 and 15 years 
follow-up in two populations treated according to 
well-defined regimens and with systematic assess-
ment of anti-tumour response in two phase 2 trials.
The short-term (5-year) negative prognostic 
impact of TP53 mutations was demonstrated in the 
recent phase 3 EOrTC 10994/Big 1-00 trial with 
928 breast cancer patients, but a predictive value of 
TP53 mutation status for anthracycline resistance was 
not seen in this trial [17]. The reason for this apparent 
discrepancy compared to our data could be due to 
higher anthracycline doses administered in the 
EOrTC 10994/Big 1-00 trial, but in particular the 
fact that these patients received cyclophosphamide 
and taxanes in concert. Notably, cyclophosphamide at 
high doses has been shown by others to compensate 
for anthracycline resistance in TP53-mutated human 
breast cancers [26], whereas TP53 status has not been 
found to predict for sensitivity to taxanes [24,27].
Notably, in multivariate analysis, TP53 mutation 
status was the only pre-treatment parameter to be 
associated with long-term outcome in our patient 
cohorts, and this finding extends the negative prog-
nostic value of TP53 mutations from previous reports 
after 7.5–10 years [16] to currently 15–20 years obser-
vation. Additionally, we observed an association 
between extensive radiation fibrosis on the chest wall 
and improved long-term prognosis in a sub-group of 
patients for whom such data were available. Conflict-
ing evidence has linked radiation fibrosis to local 
tumour control after radiotherapy, where certain 
patients seem especially sensitive to radiotherapy 
[20–22]. As both ATM and TP53 mutations have been 
related to radiation sensitivity [22,28], we compared 
ATM expression levels and ATM/TP53 mutation sta-
tus, previously analysed in a subgroup of these patients 
[23], to fibrotic status, but no correlation between 
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FUMI
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wt or non L2/L3 (n=62)
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wt or non L2/L3 (n=18)
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S
Figure 3. survival related to tumour TP53 mutation or TP53 L2/L3 domain mutation status in patients with locally advanced breast cancer 
given neoadjuvant doxorubicin (A–D) or FUMi (E–H). Os, overall survival (patients with stage iV disease excluded); rFs, recurrence-
free survival. Number of patients per group given in parenthesis. Censored values are marked with .
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neither ATM nor TP53 status and radiation-induced 
fibrosis was recorded. While patients who developed 
chest wall fibrosis had prolonged Os, this finding 
could be confounded by increased time to develop 
fibrosis only in the long-time survivors.
Clearly, more efficient chemotherapy regimens 
and less toxic radiotherapy techniques have improved 
the outcome in patients with LABC quite extensively 
over the past 15–20 years, compared to treatment 
schedules given in the doxorubicin and FUMi trials. 
Thus, the clinical relevance of our findings relates 
to the persistent negative prognostic impact of TP53 
inactivating mutations in LABC, observed after 
15–20 years follow-up. While TP53 mutations are 
associated with inferior breast cancer prognosis in 
general, our findings reveal that the negative predic-
tive value of TP53 mutation status in patients treated 
with an anthracycline or mitomycin-containing regi-
men translates into inferior long-term survival in 
locally advanced breast cancer. 
(A)
(C)
(E)
(B)
(D)
(F)
R
FS O
S
Time (months) Time (months)
TP53 : p<0.001
N:       p=0.20
Time (months) Time (months)
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O
S
O
S
R
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R
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Dox/FUMI
FUMI
Dox
Dox/FUMI
FUMI
TP53 : p<0.001
N:       p=0.22
TP53 : p=0.049
N:       p=0.87
TP53 : p=0.081
N:       p=0.79
TP53 : p=0.003
N:       p=0.15
TP53 : p=0.001
N:       p=0.21
TP53 wt, N0 (n=23)
----TP53 mut, N0 (n=4)
TP53 wt, N1-2 (n=33)
----TP53 mut, N1-2 (n=18)
TP53 wt, N0 (n=5)
----TP53 mut, N0 (n=3)
TP53 wt, N1-2 (n=7)
----TP53 mut, N1-2 (n=9)
TP53 wt, N0 (n=28)
----TP53 mut, N0 (n=7)
TP53 wt, N1-2 (n=40)
----TP53 mut, N1-2 (n=27)
Figure 4. Multivariate analysis of survival outcome with respect to tumour TP53 and clinical nodal status (N) in patients with locally 
advanced breast cancer from the doxorubicin trial (A,B), the FUMi trial (C,D) or the two trials combined (E,F). Os, overall survival 
(patients with stage iV disease excluded); rFs, recurrence-free survival. Number of patients per group given in parenthesis. Censored 
values are marked with .
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